Compare MPLX LP (MPLX) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs Natera Inc. Common Stock — how do they compare? MPLX LP trades at $57.5 (market cap $58.26B), while Natera Inc. Common Stock trades at $392.66 (market cap $57.03B). The key difference: MPLX LP and Natera Inc. Common Stock are close in size by market cap, and MPLX LP pays a 7.49% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals.
| MPLX | NTRA | |
|---|---|---|
Market Cap | $58.26B | $57.03B |
Volume | 2,089,896 | 1,131,157 |
Sector | Energy | Health |
52-Week High | $60.51 | $425.64 |
52-Week Low | $48.53 | $179.42 |
Enterprise Value | $83.36B | $56.18B |
Dividend Yield | 7.49% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $56.91 with minimal daily movement (+0.14%). Technical indicators show a bearish trend while fundamentals remain strong with a 40.45% net income margin and 33.95% ROE. The company maintains robust cash flow generation of $5.91B from operations in 2025, supporting its $1.08 dividend. Recent earnings showed mixed results with one beat and two misses in the last three quarters.
Wall Street maintains a bullish outlook with 19 buy ratings and a $63.80 consensus price target, representing 12% upside potential. Key risks include energy market volatility and execution challenges, but MPLX's fee-based revenue model provides stability. The stock offers value at a 12.36 P/E ratio with dividend income appeal.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
